Recent studies highlight a novel mechanism by which DCs utilize IgE-FcεRI interactions for cross-presentation of tumor antigens, activating cytotoxic CD8+ T lymphocytes (CTLs) even at low antigen doses. This evidence concerns the gene FCER1A and neoplasm.